Atosiban

Atosiban
(IUPAC) ime
	1-(3-mercaptopropanoic acid)-; 2-(O-ethyl-D-tyrosine)-4-L-threonine-; 8-L-ornithine-oxytocin
Klinički podaci
Identifikatori
CAS broj	90779-69-4
ATC kod	G02CX01
PubChem	5311010
ChemSpider	4470550
KEGG	D03008
ChEMBL	CHEMBL378642
Hemijski podaci
Formula	C43H67N11O12S2
Mol. masa	994.199
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1; Key: VWXRQYYUEIYXCZ-OBIMUBPZSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	intravenozno

Atosiban (Traktocil, Antocin) je inhibitor hormona oksitocina i vazopresina. On se koristi kao intravenozni lek za sprečavanje preranog porođaja (tokolitik). Mada su inicijalna ispitivanja pokazala da može da se koristi kao nazalni sprej, i da stoga bolničko lečenje nije neophodno, on se ne koristi u toj formi. Atosiban je razvila švedska kompanija Fering Farmaceutikals, i prvi izveštaji su objavljeni 1985.^[6]

Atosiban je modifikovana forma oksitocina koja inhibira dejstvo tog hormona u materici, što dovodi do prestanka porođajnih kontrakcija.

Jedan sistematski pregled iz 2005. je pokazao da mada atosiban ima manje nuspojava nego alternativni lekovi (kao što je ritodrin), on nije bolji od plasiba, i u jednoj studiji je imao gore neonatalne ishode. Autori sugerišu da je nifedipin možda delotvorniji.^[7]

Literatura[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Akerlund M, Carlsson AM, Melin P, Trojnar J (1985). „The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin”. Acta Obstet Gynecol Scand. 64 (6): 499–504. DOI:10.3109/00016348509156728. PMID 4061066.
↑ Papatsonis D, Flenady V, Cole S, Liley H (2005). „Oxytocin receptor antagonists for inhibiting preterm labour”. Cochrane database of systematic reviews (Online) (3): CD004452. DOI:10.1002/14651858.CD004452.pub2. PMID 16034931.

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

Šablon:Neuropeptidni ligandi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Akerlund M, Carlsson AM, Melin P, Trojnar J (1985). „The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin”. Acta Obstet Gynecol Scand. 64 (6): 499–504. DOI:10.3109/00016348509156728. PMID 4061066.

[7] Papatsonis D, Flenady V, Cole S, Liley H (2005). „Oxytocin receptor antagonists for inhibiting preterm labour”. Cochrane database of systematic reviews (Online) (3): CD004452. DOI:10.1002/14651858.CD004452.pub2. PMID 16034931.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Atosiban

Literatura[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga